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Abstract
Introduction: Pramipexole is a new dopaminergic drug which has been approved for PD
treatment. However, we tried to find new capacity for this drug rather than symptomatic
effect. Materials and Methods: A chronic rotenone model with daily oral dose of
30mg/kg was induced in mice. Pramipexole was tried in a new approach where the
treatment began in the middle of rotenone course with oral dose 1mg/kg /day of
pramipexole. Results: Further analysis of behavioral tests and immunohistochemistry
revealed success of pramipexole in improving the rotenone intoxicated mice. Conclusion:
These results showed possible beneficial effect of pramipexole against rotenone induced
neurotoxicity.
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1- Introduction:
Parkinson’s disease (PD) is a major health concern to the population.
It has been reported in all countries and in all races (Obeso et al., 2010).
Parkinsonism results primarily from abnormalities of basal ganglia
function (Galvan and Whichmann, 2008).   In PD, the degeneration of
dopaminergic SNc neurons and their projections to the striatum is a
slowly evolving process that may take decades to develop (Arias-
Carrión et al., 2009). PD is considered a multifactorial disease resulting
from the effect of environmental factors and genetic susceptibility,
however, due to delay of manifestations it is difficult to attribute - with
certainty- PD to certain risk factor (Caldwell et al., 2009). Various
treatment modalities are used for PD however, due to the lack of
understanding of PD etiology and pathogenesis, there is still no treatment
that can prevent or retard the progression of the disease (Lohle and
Reichmann, 2010).
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2The NIH Committee to Identify Neuroprotective Agents in
Parkinson’s (CINAP) published the result of a systematic assessment of
currently available pharmacologic neuroprotective agents. The CINAP
members stated the importance of using PD models in testing drugs
(Emborg 2004). Rotenone model can be used as an alternative to other
classical PD models e.g. MPTP and 6-OHDA specially when testing the
neuroprotective effects of novel therapeutic modalities (Monti et al.
2009). A limiting factor of rotenone models is the high mortality rate of
the examined animals (Dawson et al. 2002). However, oral rotenone
model seems to be devoid of the previous drawbacks which promote its
use for assessing candidate antiparkinson drugs (Takeuchi et al. 2009).
The introduction of second-generation dopamine agonists appeared as
new promising approach for symptomatic treatment (Kano et al., 2008).
These new dopamine receptor agonists are potent in controlling primary
motor symptoms, with little side effects as compared with the old
generations (Toulouse and Sullivan 2008). Moreover, the so called
‘direct’ dopamine receptor agonists can function in the absence of host
dopamine neurons, as they act directly on post synaptic dopamine
receptors (Hedlund and Perlmann 2009). May be, through releasing
dopamine, pramipexole has shown capacity to direct neural stem cells
(NSCs) differentiation towards dopaminergic neurons (Riaz and
Bradford 2005; Winner et al. 2009).
In the present work we tried pramipexole in the middle of toxic exposure
course in a way similar to the natural disease history. In clinical trials
pramipexole is given after the manifestations of PD appears (i.e. losing
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380% of DA neurons). In such scenario the regenerative capacity is more
important. Assessing the neuro-regenrative effects of pramipexole
(besides its known neuroprotective effects) was our main question.
2- Materials and methods:
2-1. Rotenone mouse model and drug administration:
Eight-month-old male BALB/c mice (20–25 g) were purchased from
vacsera animal house (Cairo, Egypt). All animal experiments were
carried out in accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals, and the protocols were
approved by the Ethical Committee for Research at Mansoura University.
The mice were divided into 3 groups (10 mice each):
Group (1) [control group] Received only carboxymethyl cellulose orally
(through gavage) once daily at a volume of 10 ml/kg body weight
Group (2) [Rotenone group] in this group:
Rotenone (Sigma, St. Louis, MO, USA) was administered orally (through
gavage) once a day at a dose of 30 mg/kg for 28 days, as described
previously (Inden et al. 2007). Rotenone was suspended in 0.5%
carboxymethyl cellulose sodium salt (CMC, El Nasr company, Cairo,
Egypt) and administered once daily at a volume of 10 mL/kg body
weight.
Group (3) [Pramipexole group]: in this group Pramipexole (1 mg / kg
body weight / day) was administrated via the drinking water to the mice
starting 14 days after beginning of rotenone course.
2-2. Behavioural test: (Vertical grid test (Kim et al. 2010))
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4The vertical grid apparatus is an open box of 8 cm×55 cm×5 cm, set
vertically. The back side of the vertically standing box is made of a wire
mesh of 0.8 cm×0.8 cm, the front side is open, and the other four sides
are made of black plexiglass.
The mice were pretrained on the apparatus before applying the test.
During the test, a mouse was carefully placed inside the apparatus at 3cm
from the top, facing upward, and was allowed to turn around and climb
down. The trials were videotaped.
The videos were replayed for analysis of the total time taken for the
mouse to make a turn, climb down, and reach the floor by its forepaw.
The test was made beginning from the 14th day and repeated weakly till
the 28th day. The repeated behavioral tests aimed at monitoring the
progress of PD manifestations.
2-3. Immunohistochemistry:
A prior pilot study was made, where the immunopathology revealed
decrease in TH neuron number in SN. The damage was increased with
progress of time from the 14th day till reaching maximum degeneration in
the 28th day.  According to the pilot study treated mice were perfused in
the 28th day through the aorta with 50 mL of 10 mM phosphate-buffered
saline (PBS), followed by 150 mL of a cold fixative consisting of 4%
paraformaldehyde, 0.35% glutaraldehyde and 0.2% picric acid in 100
mMphosphate buffer (PB), under deep anesthesia with pentobarbital (100
mg/ kg, i.p.). After perfusion, the brain was quickly removed and
postfixed for 2 days with paraformaldehyde in 100 mMPB and then
transferred to 15% sucrose solution in 100 mMPB containing 0.1%
sodium azide at 4 oC. The brain pieces were cut using a cryostat and
collected in 100 mM PBS containing 0.3% Triton X-100 (PBS-T). After
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5several washes, the sections were stored until use in a free-floating state
at 4 oC for immunohistochemical analysis.
Brain slices were incubated with primary mouse monoclonal anti-TH
antibody (diluted 1:1,000 Sigma) over the night at 4 oC. After several
washes, sections were incubated with biotinylated secondary antibody
(1:500), as appropriate, for 1 h at room temperature. The sections were
then incubated with ABC solution 1:200 for 1 h at room temperature. All
of the sections were washed several times with PBS-T between each
incubation, and labeling was then revealed by 3,3'-diaminobenzidine
(DAB).
2-4. Stereological analysis of DA neurons in the ventral midbrain:
TH-immunopositive neurons in the substantia nigra pars compacta
(SNpc) were estimated using stereological counts of cell numbers, on a
Stereo-investigator system and optical density measurements on a Leica
Q-win system). Six sections (30 µm-thick), from the anterior to the
posterior midbrain, were used for counting in each case. The total number
of TH-immunopositive neurons was estimated using the optical
fractionator method.
2-5 Statistical methods:
All data were given as the mean + standard error of the mean (SEM).
Two groups of data where analyzed by the Student's t-test. Three groups
of data were analyzed by ANOVA with a Tukey post hoc test. For all
tests, p<0.05 was deemed significant.
3-Results:
3-1. development of progressive PD model:
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6Regarding the locomotor affection of the mice,  the control mice usually
take about 10 seconds to complete the vertical grid test. On the other
hand, the period increased with progress of time from 14-21-28th day
where the rotenone group has taken more than 80 seconds to complete the
test (Table 2A). This progressive deterioration of locomotor functions of
the mice points to the progressive nature of the induced PD model.
As shown in (Fig. 1B), the oral administration of rotenone at 30 mg/kg
for 28 days obviously reduced the number of TH-immunopositive
neurons in the SNpc. Stereological analysis of nigral TH-immunopositive
neurons showed that rotenone caused a significant loss of DA neurons
(Table 1). It is important to mention that the pilot study showed that the
number of TH +ve neurons was decreased with progress of time (after 14
and 21 days), denoting the progressive nature of this model.
3-2. Effect of pramipexole on nigrostriatal DA neurons in rotenone mice
On investigating whether treatment with pramipexole (oral 1 mg/kg/ day
for 14 days) can offers neuroprotection against the effects caused by the
chronic oral administration of rotenone. The rotenone-induced loss of
TH-immunopositive neurons in the SNpc was significantly improved by
the pramipexole treatment (Fig. 1B and 1C).
3-3. Effect of pramipexole on locomotor coordination in rotenone mice.
In our study the control mice usually took about 10 seconds to complete
the vertical grid test. On the other hand the rotenone group has taken
more than 80 seconds to complete the test (Table 2A). On studying the
effect of treatment we can see that the pramipexole group took about 18
seconds to complete the test which represents a significant improvement
in their activity (Table 2B).
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74-Discussion:
One of the major drawbacks of rotenone models for PD was the high
mortality rates associated with their parenteral administration (Lapointe
et al. 2004). This high mortality may lead to inconsistency of results
(Cicchetti et al. 2010). Despite this major drawback, rotenone models are
characterized by many advantages making them more related to the
pathogenesis and pathology of idiopathic PD so mimicking the clinical
reality (Moussa et al. 2008; Greene et al. 2009; Verma and Nehru
2009). Moreover, rotenone models have been found ideal to test the
proposed therapies due to the chronic course they have and the similarity
with PD pathology to great extent (Mao et al. 2007; meurers et al. 2009;
Greenamyre et al. 2010). In the present study we have got a rotenone
model with 0% mortality and on the other hand induced effective
progressive PD manifestations as can be seen from the deterioration in
behavioral tests and immunohistochemical examination results with
progress of time.
Usually PD therapies were tested in two ways. The first is to test the
effect of the therapy after complete development of the injury (Fu et al.
2006; Weiss et al. 2006; Hall et al. 2007; Kong et al. 2008; Blandini et
al. 2010). The other, is testing the neuroprotectant effects e.g. nicotine or
pramipexole against toxic models (Inden et al. 2009 and Takeuchi et al.
2009). In this way, the therapy is given in the beginning of the toxic
model seems an attractive point of research. However, in the present
study we tried to explore the role of pramipexole in a way similar to
clinical real life, where the drug is given in the middle of the disease
course (i.e. regenerate damaged neurons and at the same time offers
neuroprotection for the rest of the others). Our results show that
pramipexole improved the disease both functionally (behavioral tests) and
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8structurally (immunohistochemistry). Inden and colleagues have
suggested multiple mechanisms for pramipexole effects on PD pathology
e.g. inhibition of oligomerization of human wild-type ά-synuclein by
H2O2 plus cytochrome c, directly scavenged hydroxyl radical (OH)
generated from H2O2 and Fe2+ and increased Bcl-2 immunoreactivity in
DA neurons in the SNpc. In the present study we suggest new mechanism
which is regeneration of damaged dopaminergic neurons in the SN. This
damage is caused by 14 day treatment of rotenone before we began the
pramipexole therapy. The regenerated neurons points to the fact that
pramipexole can be valuable as neuroregenerative therapy and not only
neuroprotectant as suggested by previous studies.
5-Conclusion:
In conclusion, the chronic oral administration of rotenone induced DA
neuronal death and was associated with a motor deficit. This pathology
was improved by the dopaminergic agent pramipexole that was given in
the middle of the toxic model. These results suggest that pramipexole can
improve the pathological condition and not just a symptomatic therapy
for PD.
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Tables and Figure Legends:
Table 1: Stereological cell counts in substantia nigra
A)Control group B)Rotenone group C)Rotenone+pramipexole
group
1970+ 120 1000 + 56* 1930 + 88
*p < 0.05 compared to the control group.
Table 2: vertical grid test results:
Groups A)Control group B) rotenone
group.
C) rotenone +
pramipexole
group.
Total time to
climb down
10.9 + 2.4 83.7+ 6.8* 18.7+3.4
*p < 0.05 compared to the control group.
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1-A                               1-B 1-C
Fig. 1: Tyrosine hydroxylase immunohistochemistry  in the control group
(1-A), the rotenone group (1-B) and the rotenone+ pramipexole group (1-
C). Medium magnification images in dorsolateral region of nigra show
cell loss in this particularly vulnerable area in the rotenone group with
regeneration in the rotenone+pramipexole group.
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